Innovative Therapeutic Strategies in the Molecular Targeting Era

Author(s): Jun-Ichi Nishimura

Journal Name: Current Medicinal Chemistry

Volume 27 , Issue 25 , 2020


Become EABM
Become Reviewer
Call for Editor

[1]
Rother, R.P.; Rollins, S.A.; Mojcik, C.F.; Brodsky, R.A.; Bell, L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol., 2007, 25(11), 1256-64.
[http://dx.doi.org/10.1038/nbt1344] [PMID: 17989688]
[2]
Nishimura, J.; Yamamoto, M.; Hayashi, S.; Ohyashiki, K.; Ando, K.; Brodsky, A.L.; Noji, H.; Kitamura, K.; Eto, T.; Takahashi, T.; Masuko, M.; Matsumoto, T.; Wano, Y.; Shichishima, T.; Shibayama, H.; Hase, M.; Li, L.; Johnson, K.; Lazarowski, A.; Tamburini, P.; Inazawa, J.; Kinoshita, T.; Kanakura, Y. Genetic variants in C5 and poor response to eculizumab. N. Engl. J. Med., 2014, 370(7), 632-639.
[http://dx.doi.org/10.1056/NEJMoa1311084] [PMID: 24521109]
[3]
Fukuzawa, T.; Nezu, J. SKY59, a novel recycling antibody for complement-mediated diseases. Curr. Med. Chem., 2020, 27(25), 4157-4164.
[http://dx.doi.org/10.2174/0929867326666191016115853] [PMID: 31622197]
[4]
Wiles, J.A.; Galvan, M.D.; Podos, S.D.; Geffner, M.; Huang, M. Discovery and development of the oral complement factor D inhibitor ACH-4471. Curr. Med. Chem., 2020, 27(25), 4165-4180.
[http://dx.doi.org/10.2174/0929867326666191001130342] [PMID: 31573880]
[5]
Nimjee, S.M.; Sullenger, B.A. Therapeutic aptamers: Evolving to find their clinical niche. Curr. Med. Chem., 2020, 27(25), 4181-4193.
[http://dx.doi.org/10.2174/0929867326666191001125101] [PMID: 31573879]


free to download

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 25
Year: 2020
Published on: 22 July, 2020
Page: [4155 - 4156]
Pages: 2
DOI: 10.2174/092986732725200619144223

Article Metrics

PDF: 23
HTML: 2